Related Experiment Video

Updated: Jun 10, 2026

Assays for Validating Histone Acetyltransferase Inhibitors
09:11

Assays for Validating Histone Acetyltransferase Inhibitors

Published on: August 6, 2020

Cell type-specific anti-cancer properties of valproic acid: independent effects on HDAC activity and Erk1/2

Kamil Gotfryd1, Galina Skladchikova, Eugene A Lepekhin

  • 1Protein Laboratory, Department of Neuroscience and Pharmacology, Faculty of Health Sciences, University of Copenhagen, Denmark.

BMC Cancer
|July 29, 2010
PubMed
Abstract

Insights

Valproic acid (VPA) affects cancer cell Erk1/2 phosphorylation independently of HDAC inhibition, influencing cell speed and anti-cancer properties. This highlights VPA

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Valproic acid (VPA), an anti-epileptic drug, shows potential as an anti-cancer agent.
  • Investigating VPA's anti-cancer mechanisms is crucial for therapeutic development.

Purpose of the Study:

  • To examine VPA's effects on histone deacetylase (HDAC) inhibition, cell growth, motility, and Erk1/2 phosphorylation.
  • To determine the relationship between HDAC inhibition and VPA's impact on cellular processes.
  • To elucidate the role of Erk1/2 phosphorylation in VPA's anti-cancer effects.

Main Methods:

  • Exposure of 10 distinct cell lines to VPA.
  • Assay of HDAC inhibition levels.
  • Measurement of cell growth, speed, and Erk1/2 phosphorylation.
  • Analysis of the MAPK pathway modulation.

Main Results:

  • VPA induced cell type-specific HDAC inhibition.
  • VPA modulated cell growth, motility, and Erk1/2 phosphorylation in a cell-specific manner.
  • No correlation was observed between HDAC inhibition and changes in Erk1/2 phosphorylation, cell growth, or motility.
  • VPA-induced modulation of the MAPK pathway at Raf impacted cell speed.

Conclusions:

  • VPA modulates Erk1/2 phosphorylation independently of HDAC inhibition.
  • Erk1/2 phosphorylation changes are significant for VPA's anti-cancer properties.
  • VPA's anti-cancer effects are linked to MAPK pathway modulation affecting cell motility.

More Related Videos

Examination of Proteins Bound to Nascent DNA in Mammalian Cells Using BrdU-ChIP-Slot-Western Technique09:14

Examination of Proteins Bound to Nascent DNA in Mammalian Cells Using BrdU-ChIP-Slot-Western Technique

Published on: January 14, 2016

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS09:20

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS

Published on: August 10, 2017

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Covalently Linked Protein Regulators02:04

Covalently Linked Protein Regulators

Proteins can undergo many types of post-translational modifications, often in response to changes in their environment. These modifications play an important role in the function and stability of these proteins. Covalently linked molecules include functional groups, such as methyl, acetyl, and phosphate groups, and also small proteins, such as ubiquitin. There are around 200 different types of covalent regulators that have been identified.
These groups modify specific amino acids in a protein.
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...